Why the study?
Does the induction of lipophagy using a synthetic adaptor protein, alpelisib, or digoxin mitigate steatosis and hepatitis in a diet-induced mouse NASH model?
Does the induction of lipophagy using a synthetic adaptor protein, alpelisib, or digoxin mitigate steatosis and hepatitis in a diet-induced mouse NASH model?
Answers are grounded in this paper and cite their sources.
Inducing lipophagy via synthetic adaptor proteins or clinically approved drugs like alpelisib and digoxin represents a promising therapeutic approach to prevent NASH progression.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lewis et al. (1963) studied Nonalcoholic steatohepatitis (NASH). Lipophagy activation (synthetic adaptor protein, alpelisib, or digoxin) was evaluated on Steatosis and hepatitis progression.
Synapse has enriched 10 related papers. Consider them for comparative context: